StockNews.AI
SMMT
StockNews.AI
74 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.  - SMMT

1. Pomerantz LLP investigates potential securities fraud at Summit Therapeutics. 2. SMMT shares fell 30.5% after disappointing Phase III trial results. 3. Ivonescimab showed some efficacy but lacked significant overall survival improvement. 4. Investors are urged to contact Pomerantz LLP regarding claims against Summit. 5. Past legal actions by Pomerantz suggest potential significant financial repercussions.

3m saved
Insight
Article

FAQ

Why Very Bearish?

The significant drop in SMMT's stock price suggests investor loss of confidence resulting from failed clinical trial results, which negatively impacted perceived value and future prospects, similar to cases like Athersys Inc. where stock prices fell sharply after unmet clinical expectations.

How important is it?

Legal investigations can severely impact stock value and investor sentiment, evident from previous securities fraud cases that resulted in significant financial liabilities and further scrutiny.

Why Short Term?

The immediate impact is evident from the stock price drop, but ongoing investigations may have longer-term consequences based on findings.

Related Companies

Athersys Inc. (ATHX)Eli Lilly and Company (LLY)Amgen Inc. (AMGN)
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Summit and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 30, 2025, Summit issued a press release “announc[ing] topline results from the Phase III clinical trial, HARMONi, the first global Phase III study evaluating ivonescimab[.]”  Although patients treated with ivonescimab and chemotherapy were 48% less likely to progress or die than patients who received chemo alone, the drug failed to make a statistically significant difference in overall survival, a metric that measures how long patients live before dying of any cause.  On this news, Summit’s stock price fell $7.99 per share, or 30.5%, to close at $18.22 per share on May 30, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes.    CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News